Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Beaufour Ipsen Pharma
Woman and Man Max 99 years
Beaufour Ipsen Pharma S.A.S
Update Il y a 4 ans
A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS)
To compare the efficacy of a single application of Dysport (100, 300 or 500 units) injected into 3 to 6 trigger points (TPs) located in the upper back musculature of adults with (MPS) with placebo
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Beaufour Ipsen Pharma
Update Il y a 4 ans
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study
To demonstrate an improvement in skeletal muscle energetics and particularly in mitochondrial oxidative phosphorylation.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Beaufour Ipsen Pharma
Update Il y a 4 ans
A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin LAR Depot (20 and 30mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated with Carcinoid Syndrome
To evaluate the efficacy of lanreotide Autogel (90 and 120 mg), compared with Sandostatin LAR Depot (20 and 30 mg), in terms of the frequency of target symptom episodes, assessed by the change ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2